Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have been given a consensus recommendation of “Moderate Buy” by the seventeen research firms that are covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $25.56.

A number of analysts recently weighed in on the company. Raymond James restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th. UBS Group decreased their target price on shares of ACADIA Pharmaceuticals from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Royal Bank of Canada decreased their price objective on shares of ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Finally, Cantor Fitzgerald dropped their target price on shares of ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th.

Insider Buying and Selling at ACADIA Pharmaceuticals

In related news, insider James Kihara sold 4,073 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $68,467.13. Following the sale, the insider now owns 19,863 shares in the company, valued at approximately $333,897.03. This trade represents a 17.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Mark C. Schneyer sold 10,259 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $172,453.79. Following the completion of the sale, the chief financial officer now directly owns 53,302 shares of the company’s stock, valued at $896,006.62. The trade was a 16.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 24,661 shares of company stock worth $414,551. Corporate insiders own 28.30% of the company’s stock.

Institutional Trading of ACADIA Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Park Place Capital Corp purchased a new position in shares of ACADIA Pharmaceuticals during the 3rd quarter worth about $25,000. Values First Advisors Inc. acquired a new position in ACADIA Pharmaceuticals during the third quarter worth approximately $27,000. Covestor Ltd raised its stake in ACADIA Pharmaceuticals by 70.5% during the first quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 840 shares during the period. Headlands Technologies LLC purchased a new position in ACADIA Pharmaceuticals during the first quarter worth approximately $48,000. Finally, Quest Partners LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 42.3% in the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 1,047 shares during the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Stock Performance

ACAD stock opened at $16.21 on Wednesday. The stock has a market capitalization of $2.70 billion, a PE ratio of 20.78 and a beta of 0.38. The company has a fifty day moving average of $15.60 and a 200-day moving average of $15.99. ACADIA Pharmaceuticals has a one year low of $14.15 and a one year high of $32.59.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.06. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The firm had revenue of $250.40 million during the quarter, compared to the consensus estimate of $248.83 million. During the same quarter last year, the firm earned ($0.40) earnings per share. The firm’s revenue was up 18.3% compared to the same quarter last year. Equities analysts forecast that ACADIA Pharmaceuticals will post 0.72 earnings per share for the current fiscal year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.